Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA

Emily P. Thi, Chad Mire, Raul Ursic-Bedoya, Joan B. Geisbert, Amy C H Lee, Krystle N. Agans, Marjorie Robbins, Daniel J. Deer, Karla A. Fenton, Ian MacLachlan, Thomas Geisbert

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.

Original languageEnglish (US)
Article number250ra116
JournalScience Translational Medicine
Volume6
Issue number250
DOIs
StatePublished - Aug 20 2014

Fingerprint

Marburgvirus
Virus Diseases
Angola
Primates
Small Interfering RNA
Lipids
Nanoparticles
Viruses
Fever
Therapeutics
Ebolavirus
Mortality
Macaca
Infection
Macaca mulatta
Disease Outbreaks
Vaccines
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Marburg virus infection in nonhuman primates : Therapeutic treatment by lipid-encapsulated siRNA. / Thi, Emily P.; Mire, Chad; Ursic-Bedoya, Raul; Geisbert, Joan B.; Lee, Amy C H; Agans, Krystle N.; Robbins, Marjorie; Deer, Daniel J.; Fenton, Karla A.; MacLachlan, Ian; Geisbert, Thomas.

In: Science Translational Medicine, Vol. 6, No. 250, 250ra116, 20.08.2014.

Research output: Contribution to journalArticle

Thi, EP, Mire, C, Ursic-Bedoya, R, Geisbert, JB, Lee, ACH, Agans, KN, Robbins, M, Deer, DJ, Fenton, KA, MacLachlan, I & Geisbert, T 2014, 'Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA', Science Translational Medicine, vol. 6, no. 250, 250ra116. https://doi.org/10.1126/scitranslmed.3009706
Thi, Emily P. ; Mire, Chad ; Ursic-Bedoya, Raul ; Geisbert, Joan B. ; Lee, Amy C H ; Agans, Krystle N. ; Robbins, Marjorie ; Deer, Daniel J. ; Fenton, Karla A. ; MacLachlan, Ian ; Geisbert, Thomas. / Marburg virus infection in nonhuman primates : Therapeutic treatment by lipid-encapsulated siRNA. In: Science Translational Medicine. 2014 ; Vol. 6, No. 250.
@article{e0d4f0315bdc488882c193ff9fdbbc02,
title = "Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA",
abstract = "Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90{\%}. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.",
author = "Thi, {Emily P.} and Chad Mire and Raul Ursic-Bedoya and Geisbert, {Joan B.} and Lee, {Amy C H} and Agans, {Krystle N.} and Marjorie Robbins and Deer, {Daniel J.} and Fenton, {Karla A.} and Ian MacLachlan and Thomas Geisbert",
year = "2014",
month = "8",
day = "20",
doi = "10.1126/scitranslmed.3009706",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "250",

}

TY - JOUR

T1 - Marburg virus infection in nonhuman primates

T2 - Therapeutic treatment by lipid-encapsulated siRNA

AU - Thi, Emily P.

AU - Mire, Chad

AU - Ursic-Bedoya, Raul

AU - Geisbert, Joan B.

AU - Lee, Amy C H

AU - Agans, Krystle N.

AU - Robbins, Marjorie

AU - Deer, Daniel J.

AU - Fenton, Karla A.

AU - MacLachlan, Ian

AU - Geisbert, Thomas

PY - 2014/8/20

Y1 - 2014/8/20

N2 - Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.

AB - Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.

UR - http://www.scopus.com/inward/record.url?scp=84907409689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907409689&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3009706

DO - 10.1126/scitranslmed.3009706

M3 - Article

C2 - 25143366

AN - SCOPUS:84907409689

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 250

M1 - 250ra116

ER -